BackgroundSMYD3 (SET and MYND domain containing 3) is a member of the SMYD family of protein methyltransferases. All family members (SMYD1, SMYD2, SMYD3, SMYD4, and SMYD5) contain a conserved catalytic SET domain, first identified in Drosophila Su[var]3-9, Enhancer of zeste, and Trithorax proteins. SMYD3 can be overexpressed in several different cancers, including breast, colorectal, and liver cancer. Research shows that cancer cells may express full-length and a more active cleaved SMYD3 that lack the first 34 amino acids at the N-terminus. The N-terminus of full-length of this gene interacts with Hsp90alpha and enhances its activity. This indicates that the N-terminal region may participate in regulating methyltransferase activity.
DescriptionSMYD3 Polyclonal Antibody. Unconjugated. Raised in: Rabbit.
Formulation Liquid. PBS with 0.02% sodium azide, pH7.3.
SpecificityHuman
IsotypeIgG
Uniprot IDQ9H7B4
PurificationAffinity Purified
ImmunogenSynthetic Peptide of Human SMYD3
StorageShipped at 4°C. Store at -20°C. Avoid multiple freeze/thaw cycles.
Alternative NamesKMT3E, ZMYND1, ZNFN3A1, bA74P14.1
ApplicationWB, FC; Recommended dilution: WB 1:200 - 1:1000, FC 1:20 - 1:50